🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🫀Stay updated with Italian Cardiologists Of Tomorrow 📌Which is the Contribution of AF to In-Hospital Mortality in Patients With COVID-19? 💡AF, especially new-onset, is an independent predictor of in-hospital mortality, CV death, and more severe clinical pattern in patients with COVID-19.

Last day of TOBI Total Occlusion Bifurcation Interventions 2022! Great success and nice debates, 16 live cases and terrific international faculty! Thanks to directors Jacopo Oreglia, Gabriele Gasparini, Bernhard Reimers, all the faculty, as well as attendees, patients, nurses and companies! See you next Nov 8-9-10

How to improve antithrombotic therapy net benefit and the promising role of novel FXIa inhibitors. Terrific session held by Dr Roxana Mehran and Professor Vijay Kunadian at CVCT - CardioVascular Clinical Trialists in Washington DC. #cvct2022 #thrombosis #trialist

Take a look to our review about AI application for CV risk prediction just published on #ECRjournal 👉 ecrjournal.com/articles/artif… Radcliffe Cardiology Mauro Chiarito Giulio Stefanini @gcondorelli #ArtificialIntelligence #Cardiology

🚨Hot off the press network meta-analysis European Society of Cardiology Journals on the available #antithrombotic treatments within or after 12 months following MI and PCI‼️ Full text at European Heart Journal - Cardiovascular Pharmacotherapy #EHJPharmacotherapy ➡️ academic.oup.com/ehjcvp/advance… A 🧵

So proud to see our network metanalysis on antithrombotic strategies in patients with CAD finally published in #EHJPharmacotherapy. +40 trials and 250k patients included. This paper informed the upcoming EAPCI/ACVC/EAPC consensus document. Stay tuned! academic.oup.com/ehjcvp/advance…

Ticagrelor Monotherapy reduced bleeding without increasing ischemic events in 7,529 ACS patients from TWILIGHT and TICO trials pooled analysis Our study led by Dr Roxana Mehran and presented by Usman Baber at #TCT2023 simultaneously published in Circulation ahajournals.org/doi/10.1161/CI…

DCB vs. DES for LAD PCI. A Featured Science Presentation @CRF #TCT2023 published simultaneously in circinterventions.ahajournals.org. ahajournals.org/doi/abs/10.116… Mauro Gitto Alessandro Sticchi Mauro Chiarito Antonio Colombo #TCTConference #ACCFIT #AHAJournals

#TCT2023 - Superb presentation by Dr Roxana Mehran on our work with the xDAPT model 🤖💡Machine learning showed excellent performance in predicting ischemic and bleeding risk post-PCI. Risk scores just got a game-changer! #MachineLearning #PCI TCT Conference

Fantastic opportunity to present new #DCB 3.0 registry data from Humanitas Milano Exciting sessions including: - Everolimus-eluting 🎈 - SCB vs. PCB - TRANSFORM I So much more coming! Antonio Colombo Bernardo Cortese #BrunoScheller #PatrickSerruys #ManelSabatè

#JustPublished: #CircTCT23 Ticagrelor monotherapy in ACS patients ahajournals.org/doi/10.1161/CI…

Check out this article: cnn.com/2023/10/31/hea… Great to see this covered by CNN Cardiovascular Research Foundation #TWILIGHT #TICO Marco Valgimigli Davide Capodanno Mount Sinai Health System Icahn School of Medicine at Mount Sinai

ORBITA-2 ⁉️PCI vs placebo in stable CAD w/no-little antianginal meds 🌎 301 pts, 12 weeks FU 🎯 PCI improved angina score+frequency (assessed daily by app 📱), exercise time, CCS and QoL 💔 NO difference in antianginal medications, but still high residual symptoms #AHA23 NEJM

All the first 5 authors of #orbita2 are UK cardiology fellows which could only have been possible under the exceptional mentorship, supervision and drive of Rasha Al-Lamee. I feel deeply humbled and proud to have been part of this incredible team! #AHA23 BCIS BJCA 📊 European Society of Cardiology

Similarities and differences between an European Expert consensus and 2023 ESC guidelines for antithrombotic management of ACS➡️just published in #EHJACVC doi:10.1093/ehjacc/zuad158 under the lead of Marco Valgimigli Dr Roxana Mehran Davide Capodanno EHJACVC Editor-in-Chief

#ACC2024 LBT: AEGIS-II ➡️4 weekly infusions of ApoA-1 vs placebo to improve cholesterol efflux after MI 🌎18,219 high-risk AMI pts wMVD (50% STEMI, 88% PCI) 💔No differences in primary endpoint at 90 days 🎯MACE, CVdeath/MI reduced in pts with LDL>100 NEJM C. Michael Gibson MD #ACC24

Be sure to join Dr. Angelo Oliva MD at #ESCCongress to learn more about his work. #CardioX #CardioTwitter Icahn School of Medicine at Mount Sinai European Society of Cardiology

Results from SYDNEY4 IPD analysis just presented by Marco Valgimigli at European Society of Cardiology and sim published. Ticagrelor mono vs DAPT in >20.000 pts from 6 RCTs, pre-specified ACS vs CCS. Is this the conclusive evidence? Read our editorial in The Lancet Giulio Stefanini thelancet.com/journals/lance…